Income statement
USD
Annual
| Metric | 2024 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -331K | 0 | 0 | 0 | 0 |
| Operating Income | -5M | -13M | -16M | -23M | 86M |
| EBITDA | -4M | -12M | -15M | -22M | 86M |
| Net Income | -8M | -4M | -25M | 118M | -163M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.07
+0.00% today
1Y Change
+133.33%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Resverlogix Corp. (RVXCF) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.07 and up 133.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -0.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -0.4%, free cash flow +14.3% with operating margin 0.0% and ROIC 33.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVXCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVXCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RVXCF Max Drawdown
-70.59%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RVXCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$162.8M
-237.9% YoY
Free Cash Flow
-$49.5M
-177.2% YoY
Revenue Growth
+0.0%
EPS Growth
-0.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -331K | 0 | 0 | 0 | 0 |
| Operating Income | -5M | -13M | -16M | -23M | 86M |
| EBITDA | -4M | -12M | -15M | -22M | 86M |
| Net Income | -8M | -4M | -25M | 118M | -163M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 99K | 40K | 6K | 4K | 8M |
| Total Assets | 7M | 8M | 10M | 11M | 16M |
| Total Liabilities | 89M | 67M | 70M | 75M | 224M |
| Shareholder Equity | -82M | -59M | -60M | -64M | -208M |
| Total Debt | 82M | 6M | 7M | 13M | 15M |
| Net Debt | 82M | 6M | 7M | 13M | 7M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
49M
-181.6% YoY
Capital Expenditures
622K
-24.4% YoY
Free Cash Flow
49M
-177.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
8.4%
Debt / Equity
-0.82x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.